DUAKLIR™ GENUAIR®
(ACLIDINIMUM BROMIDE/
FORMOTEROL FUMARATE)

Duaklir Genuair is an inhaled medication for the treatment of COPD (chronic obstructive pulmonary disease) that has recently received limited provincial formulary coverage. Duaklir Genuair contains a combination of a long-acting muscarinic antagonist (LAMA) with a long-acting beta₂-agonist (LABA) in a preloaded, multi-dose inhaler device.

• **Dosage:** A multi-dose dry powder inhaler in a dose of 400 mcg aclidinium/12 mcg formoterol, one inhalation twice daily.

• **Uses:** Duaklir Genuair is a long-term treatment for residents with COPD. It is taken regularly to control symptoms and prevent exacerbations of COPD. It should *not* be used as a “rescue medication” to treat acute exacerbations of COPD or for the management of asthma.

• Another combination product that is in the same class as Duaklir Genuair is Inspiolto™ Respimat® (tiotropium/olodaterol).

Please refer to Duaklir™ Genuair® product monograph for more comprehensive information regarding inhalation technique, including warnings and precautions.

**What to Monitor**

- Shortness of Breath
- Blood Pressure
- Heart Rate
- Glucose Levels
- Potassium Levels
- Visual Changes (e.g., pain, discomfort, blurriness)
- Urine Retention (e.g., difficulty passing urine)

References: